Status:

COMPLETED

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Lead Sponsor:

University Hospital Schleswig-Holstein

Conditions:

Leukemia

Eligibility:

All Genders

1-18 years

Phase:

PHASE3

Brief Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination c...

Detailed Description

OBJECTIVES: * Compare the relative efficacy of induction therapy comprising dexamethasone or prednisone, in terms of a higher rate of event-free survival (EFS) and overall survival and a reduced rate...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed acute lymphoblastic leukemia (ALL)
  • No secondary ALL
  • PATIENT CHARACTERISTICS:
  • No prior disease that would preclude treatment with chemotherapy
  • PRIOR CONCURRENT THERAPY:
  • More than 4 weeks since prior chemotherapy
  • More than 4 weeks since prior steroids

Exclusion

    Key Trial Info

    Start Date :

    July 1 2000

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    January 1 2012

    Estimated Enrollment :

    4559 Patients enrolled

    Trial Details

    Trial ID

    NCT00430118

    Start Date

    July 1 2000

    End Date

    January 1 2012

    Last Update

    May 29 2013

    Active Locations (76)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 19 (76 locations)

    1

    Krankenhaus Dornbirn

    Dornbirn, Austria, A-6850

    2

    Landeskrankenhaus Feldkirch

    Feldkirch-Tisis, Austria, A-6807

    3

    Universitaet Kinderklinik

    Graz, Austria, 8036

    4

    Innsbruck Universitaetsklinik

    Innsbruck, Austria, A-6020

    Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia | DecenTrialz